Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.04. View Zynerba Pharmaceuticals' Earnings History.

9 analysts have issued twelve-month price targets for Zynerba Pharmaceuticals' stock. Their predictions range from $4.00 to $32.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $11.13 in the next twelve months. View Analyst Ratings for Zynerba Pharmaceuticals.

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (8/10/2017)
• 2. Maxim Group analysts commented, "Zynerba announced the completion of target pediatric patient enrollment (n=16, ages from 6 – 17 years old) in the Phase II FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study to evaluate ZYN002, Zynerba’s cannabidiol (CBD) gel in children with Fragile X syndrome (FXS)." (6/8/2017)

Zynerba Pharmaceuticals saw a decrease in short interest in the month of August. As of August 31st, there was short interest totalling 2,265,898 shares, a decrease of 25.0% from the August 15th total of 3,020,759 shares. Based on an average trading volume of 613,139 shares, the days-to-cover ratio is presently 3.7 days. Currently, 21.5% of the shares of the company are sold short.

Some companies that are related to Zynerba Pharmaceuticals include Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Genocea Biosciences (GNCA), Pluristem Therapeutics (PSTI), CTI BioPharma Corp. (CTIC), Oramed Pharmaceuticals (ORMP), GTx (GTXI), Regulus Therapeutics (RGLS), Silence Therapeutics plc (SLN), Novelion Therapeutics (NVLN), Matinas BioPharma Holdings (MTNB), BioLineRx (BLRX), CASI Pharmaceuticals (CASI), Palatin Technologies (PTN), aTyr Pharma (LIFE), Tissue Regenix Group PLC (TRX), Eiger BioPharmaceuticals (EIGR) and ArQule (ARQL).

Zynerba Pharmaceuticals' management team includes the folowing people:

• Armando Anido, Chairman of the Board, Chief Executive Officer
• Terri B. Sebree, President
• James E. Fickenscher, Chief Financial Officer, Vice President - Corporate Development
• Suzanne M. Hanlon, Secretary, General Counsel and Vice President, Human Resources
• William Roberts, Vice President - Investor Relations and Corporate Communications
• Ray Mannion, Vice President - Manufacturing
• Brian Rosenberger, Vice President - Commercial
• Warren D. Cooper M.D., Lead Independent Director
• William J. Federici, Independent Director
• Thomas L. Harrison, Independent Director

(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Zynerba Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.61%), Marshall Wace North America L.P. (2.96%), JPMorgan Chase & Co. (2.46%), Citigroup Inc. (1.67%), State Street Corp (1.20%) and Pennsylvania Trust Co (1.05%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, Michael Rapp and Suzanne M Hanlon. View Institutional Ownership Trends for Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Bluestein R H & Co., GSA Capital Partners LLP and FNY Managed Accounts LLC. View Insider Buying and Selling for Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Citigroup Inc., State Street Corp, Pennsylvania Trust Co, Northern Trust Corp, Vanguard Group Inc., Granite Point Capital Management L.P. and Virtu KCG Holdings LLC. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher and Michael Rapp. View Insider Buying and Selling for Zynerba Pharmaceuticals.

Shares of Zynerba Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Zynerba Pharmaceuticals stock can currently be purchased for approximately $6.23.